Specialized in the development of novel colonic analgesic drugs.
gIcare Pharma develops an innovative, orally-administered drug, GIC-1001, which provides colonic analgesia without the limitations and disadvantages of currently used agents. This new chemical entity is an opioid agonist capable of releasing hydrogen sulphide (H2S), a gaseous mediator providing multiple beneficial pharmacological effects. GIC-1001’s opioid agonist moiety induces viscerosensitivity modulation and exerts antinociceptive effects, which reduces the perception of pain caused by mechanical stimuli in the colon, such as colorectal distension and spasms.
- CEO Maxime Ranger
- Industry Biotech
- History Other